AS v nr-AxSpA for TNFi - no diff in response @JointMD @RheumNow #RNL2024 ADA: ASAS20 AS 58%, nr-AxSpA 52%, ASAS40 AS 39%, nr 36% (ATLAS, ABILITY-1) ETN: ASAS 20 59%/52%, ASAS50/40 44%/33% in p3 AS study v EMBARK CZP: RAPID-AxSpA - no diff bw AS & nr-AxSpA response in same trial https://t.co/Rau2CDYbY4